|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
Future Vaccine Development at NICHD
aChief, Laboratory of Developmental and Molecular Immunity, bChief, Section on Bacterial Disease, Pathogenesis and Immunity, Laboratory of Developmental and Molecular Immunity, NICHD, NIH, Bethesda, Maryland 20892, USA
John B. Robbins and Rachel Schneerson: Lasker Award, Clinical Medical Research, 1996 Address for correspondence: John B. Robbins, MD, Laboratory of Developmental and Molecular Immunity, NICHD, NIH, Building 6, Room 436, Bethesda, MD 20892, USA. Voice: 301-496-0850. robbinsj{at}nichd.nih.gov; schneerr{at}mail.nih.gov
Using published data and the results of our studies, we hypothesized that a critical level of serum IgG antibodies to the surface structures of invasive pathogens (capsular polysaccharides of Haemophilus influenzae type b, pneumococcus, meningococcus, Salmonella typhi, Escherichia coli, and Staphylococcus aureus, the O-specific polysaccharide LPS domain of the LPS of Shigella, non-typhoidal Salmonella, and E. coli, and the capsular polypeptide of Bacillus anthraces) confer immunity to these pathogens. Covalent attachment to a protein increases their immunogenicity and bestows T-cell properties to these antigens. We have also shown that a critical level of serum IgG antibodies to pertussis toxin alone induces immunity on both an individual and on a community basis (herd immunity) to Bordetella pertussis. It is likely that all the above conjugates and pertussis toxoid will be incorporated into vaccines for routine infant immunization.
Key Words: capsular polysaccharide • O-specific polysaccharide • serum IgG • capsular polypeptide • pertussis toxin This article has been cited by other articles:
| |||||||||||||||||||||||||||||
 |
 |
